![]() NeuroQuest NeuroQuest develops biomarkers for the early and accurate diagnosis of Alzheimer’s and ALS Diseases.
| ![]() Optina Diagnostics Optina Diagnostics is developing an innovative tool that will transform AD research by enabling the identification of beta-amyloid (AB) plaques, a key biomarker of the disease.
| ![]() Correlia Biosystems Correlia Biosystems is a company developing microscale tools for dynamic monitoring of protein expression profiles. | ![]() Incyclix Bio Incyclix Bio (formerly known Arc Therapeutics) is a cell cycle control company providing treatments that target the aberrant proliferation driving cancers. | ||
Founding Date | Founding Date 2008 | Founding Date 2011 | Founding Date 1995 | Founding Date 2013 | Founding Date 2020 |
Type | Type Private | Type Private | Type Private | Type Private | Type Private |
Tags | |||||
Locations | Locations Misgav, IL HQ Charleston, US | Locations Montréal, CA HQ Montréal, CA | Locations Saarbrücken, DE HQ Saarbrücken, DE | Locations Berkeley, US HQ | Locations Durham, US HQ |
Employees | Employees 13 | Employees 27 | Employees N/A | Employees 8 | Employees 10 |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 3m (over 7 years ago) | Latest funding round N/A | Latest funding round $ 7m (over 5 years ago) | Latest funding round $ 30m (about 4 years ago) |
Total funding raised | Total funding raised N/A | Total funding raised $ 3m | Total funding raised N/A | Total funding raised $ 8m | Total funding raised $ 36m |

Optina Diagnostics is developing an innovative tool that will transform AD research by enabling the identification of beta-amyloid (AB) plaques, a key biomarker of the disease.
View companyBionMed Technologies is a company specializing in medical engineering.
View company
Correlia Biosystems is a company developing microscale tools for dynamic monitoring of protein expression profiles.
View company
Incyclix Bio (formerly known Arc Therapeutics) is a cell cycle control company providing treatments that target the aberrant proliferation driving cancers.
View company